Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Lokelma

Chemical Namesodium zirconium cyclosilicate
Dosage FormSuspension (oral; 5 g, 10 g)
Drug ClassPotassium binders
SystemBlood
CompanyAstraZeneca
Approval Year2018

Indication

  • Indicated for the treatment of hyperkalemia in adults
Last updated on 4/20/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Lokelma (sodium zirconium cyclosilicate) Prescribing Information.2018AstraZeneca
Document TitleYearSource
Clinical review report: sodium zirconium cyclosilicate (Lokelma).2020CADTH
Pharmacoeconomic review: sodium zirconium cyclosilicate (Lokelma).2020CADTH
Sodium zirconium cyclosilicate for treating hyperkalaemia.2019NICE
Assessment report: Lokelma2018EMA
Australian public assessment report for sodium zirconium cyclosilicate hydrate. 2018Australian Government: Department of Health
Document TitleYearSource
Effects and safety of a novel oral potassium-lowering drug-sodium zirconium cyclosilicate for the treatment of hyperkalemia: a systematic review and meta-analysis. 2021Cardiovascular Drugs and Therapy
Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. 2020Cochrane Database of Systematic Reviews
Systematic review and meta-analysis of patiromer and sodium zirconium cyclosilicate: a new armamentarium for the treatment of hyperkalemia.2017Pharmacotherapy
Document TitleYearSource
Clinical practice guidelines: treatment of acute hyperkalaemia in adults.2019The Renal Association